Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-08-10
2010-11-02
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
Reexamination Certificate
active
07824678
ABSTRACT:
Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
REFERENCES:
patent: 7288248 (2007-10-01), Bhaskar et al.
patent: 2004/0096392 (2004-05-01), Bhaskar et al.
Agus et al., Cancer Research, Oct. 1, 1999;59(19):4761-4.
Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, p. 141-142 (1988).
Janeway et al., Chapter 3: Antigen recognition by B-Cell and T-Cell Receptors, Immunobiology 5:100-101 (2001).
Wu et al., “The Expression of Integrin alph5betal and Transforming Growth Factor-Beta in Pulmonary Fibrosis Of Rat” Chinese Journal of Pathology, 28(6): abstract (1999).
Uchida et al., “A Novel Epidermal Growth Factor-like Molecule containing Two Follistatin Modules Stimulates Tyrosine Phosphorylation of erbB-4 in MKN28 Gastric Cancer Cells”, Biochemical and Biophysical Research Comm., vol. 266, pp. 593-602(1999).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci, vol. 79, pp. 1979-1983(1982).
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J. Mol. Biol., 262:732-745 (1996).
Glynne-Jones et al., “TenB2, A Proteoglycan Identified in Prostate Cancer That is Associated with Disease Progression and Androgen Independence”, Int. J. Cancer, vol. 94, pp. 178-184 (2001).
Ford et al., “Identification of Differentially Expressed Genes Associated with Recurrent Growth of Prostate Cancer”, J. Uorology, vol. 165, No. 5, Supplement, p. 138 (2001).
Afar et al., “Preclinical validation of anti-TMEFF2-auristatin E-conjugatged antibodies in the treatment of prostate cancer”, Molecular Cancer Thereapeutics, vol. 3, No. 8, pp. 921-932 (2004).
Greenspan et al., “Defining epitopes: It's not as easy as it seems”, Nature Biotechnology, vol. 17, pp. 936-937 (1999).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science, vol. 247, No. 4948, pp. 1306-1310 (1990).
Gussow et al., “Humanization of Monoclonal Antibodies”, Methods in Enzymology, vol. 203, pp. 99-121 (1991).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”, Proc. Natl. Acad. Sci., vol. 79, pp. 1979-1983 (1982).
Gura, Trisha, “Systems for Identifying New Drugs Are Often Faulty”, Science, vol. 278, No. 5340, pp. 1041-1042 (1997).
George et al., “Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome,” Circulation, 97:900-906 (1998).
Quayle et al., “A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells,” Genomics, 87(5):633-637 (2006).
Mariuzza et al., “The structural basis of antigen-antibody recognition,” Annu. Rev. Biophys. Chem., 16:139-159 (1987).
Guisti et al.,“Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base change in its heavy chain variable region,” Proc. Natl. Acad. Sci. USA 84(9):2926-2930 (1987).
Chien et al.,“Significant structural and fnctional change of an antigen-bending site by a distant amino acid substitution: Proposal of a structural mechanism,” Proc. Natl. Acad. Sci. USA 86(14):5532-5536 (1989).
Caldas et al.,“Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen”, Mol. Immunol. 39(15):941-952 (2003).
Gery et al.,“TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells,” Oncogene, 21(31):4739-4746 (2002).
Antunes et al.,“The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis,” J. Urol. 181(2):594-600 (2009).
Afar Daniel
Bhaskar Vinay
Caras Ingrid
De La Calle Agustin
Law Debbie
Facet Biotech Corporation
Sughrue & Mion, PLLC
Yu Misook
LandOfFree
Antibodies against cancer antigen TMEFF2 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against cancer antigen TMEFF2 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against cancer antigen TMEFF2 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251343